Safety, Tolerability, and Practice Integration of Cretostimogene

The safety and tolerability profile of cretostimogene grenadenorepvec in BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) is defined by the absence of grade 3 or higher treatment-related adverse events and a 97% protocol completion rate—characteristics that Mark D. Tyson II, MD, MPH, a professor of urology at Mayo Clinic in Phoenix, Arizona, views as foundational to the agent's real-world feasibility. In the fifth segment of this program, Tyson reviews the tolerability data from BOND-003 (NCT04452591) and discusses the practical administration considerations that would shape cretostimogene's integration into standard urology practice.

Treatment-related adverse events in BOND-003 (NCT04452591) were predominantly local bladder symptoms—bladder spasms, urinary frequency and urgency, dysuria, and hematuria—all reported at grade 1 or 2, with a median time to resolution of 1 day. There were no treatment-related discontinuations. Tyson notes that 107 of 110 evaluable patients completed all protocol-specified administrations, a compliance rate he regards as meaningful evidence that the regimen is practically tolerable—efficacy data are only relevant, he emphasizes, if patients can remain on therapy long enough to benefit. He draws a direct parallel to BCG: The intravesical delivery paradigm for cretostimogene closely mirrors workflows that urology practices have used for decades, and he does not anticipate meaningful operational deviation from existing nursing and clinical protocols.

If approved, Tyson expects cretostimogene to be administered primarily by trained urology nurses, consistent with current intravesical practice, without the need for operating room time, cystoscopic procedures under anesthesia, or multidisciplinary oncology coordination. Long-term ownership of the treatment relationship, he argues, belongs within urology, given that patient selection, cystoscopic surveillance, and treatment escalation decisions are tightly linked in this population.